Heron Therapeutics Inc
NASDAQ:HRTX

Watchlist Manager
Heron Therapeutics Inc Logo
Heron Therapeutics Inc
NASDAQ:HRTX
Watchlist
Price: 1.28 USD
Market Cap: 234.7m USD

Intrinsic Value

The intrinsic value of one HRTX stock under the Base Case scenario is 2.37 USD. Compared to the current market price of 1.28 USD, Heron Therapeutics Inc is Undervalued by 46%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HRTX Intrinsic Value
2.37 USD
Undervaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Heron Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about HRTX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is HRTX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Heron Therapeutics Inc.

Explain Valuation
Compare HRTX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HRTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Heron Therapeutics Inc

Current Assets 229.4m
Cash & Short-Term Investments 55.5m
Receivables 81m
Other Current Assets 92.9m
Non-Current Assets 19.6m
PP&E 13.7m
Other Non-Current Assets 5.9m
Current Liabilities 89.7m
Accounts Payable 12m
Accrued Liabilities 77.7m
Non-Current Liabilities 144.4m
Long-Term Debt 32.2m
Other Non-Current Liabilities 112.2m
Efficiency

Free Cash Flow Analysis
Heron Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Heron Therapeutics Inc

Revenue
155.1m USD
Cost of Revenue
-40.5m USD
Gross Profit
114.6m USD
Operating Expenses
-113m USD
Operating Income
1.6m USD
Other Expenses
-15.2m USD
Net Income
-13.6m USD
Fundamental Scores

HRTX Profitability Score
Profitability Due Diligence

Heron Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

Heron Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

HRTX Solvency Score
Solvency Due Diligence

Heron Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
32/100
Solvency
Score

Heron Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HRTX Price Targets Summary
Heron Therapeutics Inc

Wall Street analysts forecast HRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HRTX is 4.59 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

Lowest
Price Target
3.03 USD
137% Upside
Average
Price Target
4.59 USD
259% Upside
Highest
Price Target
6.3 USD
392% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Heron Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for HRTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

HRTX Insider Trading
Buy and sell transactions by insiders

HRTX News

Other Videos
What is the Intrinsic Value of one HRTX stock?

The intrinsic value of one HRTX stock under the Base Case scenario is 2.37 USD.

Is HRTX stock undervalued or overvalued?

Compared to the current market price of 1.28 USD, Heron Therapeutics Inc is Undervalued by 46%.

Back to Top